To test the functional role of Tregs in EBV infection control, we treated PBMCs with RG6292, a Fc-engineered anti-CD25 antibody that depletes Tregs via ADCC while preserving IL-2 signaling to effector cells [45, 46]. Here, IL2 is linked to Epstein-Barr virus infection.